Skip to main content
Home

Search form

  • Home
  • About Heron
    • Company Overview
    • Management
    • Board of Directors
    • Contact Us
    • Careers
  • Our Focus
    • Our Mission
    • Our Technologies
    • About the 505(b)(2) Regulatory Pathway
  • Product Pipeline
    • Pipeline
    • SUSTOL®
    • HTX-019
    • HTX-011
  • Patient/​Investigator Resources
    • About Chemotherapy-Induced Nausea and Vomiting (CINV)
    • About Pain Management
    • Clinical Trials
    • Scientific Posters and Presentations
    • Publications
  • Investor Resources
    • Investor Resources Home
    • News, Events and Presentations
      • News Releases
      • Events and Webcasts
      • Corporate Presentations
    • SEC Filings
    • Stock Information
      • Stock Quote
      • Stock Chart
    • Analyst Coverage
    • Corporate Governance
      • Board of Directors
      • Committee Composition
      • Corporate Governance Documents
    • Information Request
      • Material Request
      • E-mail Alerts
      • RSS Feeds


  • Now Approved Learn more


Now Approved Learn more

Developing Best-in-Class Medicine. Improving Lives.

Recent News

September 08, 2016
|
Heron Therapeutics Announces Presentations of Results from Phase 2 Clinical Trial of HTX-011 in Hernia Repair at PAINWeek® 2016
August 29, 2016
|
Heron Therapeutics Announces Poster Presentations of Data from Phase 2 Clinical Program for HTX-011 at PAINWeek® 2016
August 10, 2016
|
Heron Therapeutics Announces U.S. FDA Approval of SUSTOL® (granisetron) Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting
More News

Quick Links

Scientific Posters and Presentations
Corporate Presentation
Pipeline
  • Home
  • About Heron
  • Our Focus
  • Product Pipeline
  • Patient/​Investigator Resources
  • Investor Resources
  • Site Map
  • Terms of Use
  • Privacy Statement
  • Careers

© 2016 Heron Therapeutics, Inc. All Rights Reserved.